NCT01584518

Brief Summary

The long-range goal of this proposal is to decrease morbidity and mortality related to pulmonary edema and congestive heart failure (CHF) in post-operative patients. The short-range goal is to determine a mechanistic endpoint when therapy for impending heart failure can be initiated and terminated based on B-type natriuretic peptide (BNP) levels. The investigators propose to utilize changing levels of BNP as a surrogate marker for CHF.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 11, 2012

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 25, 2012

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

March 28, 2016

Completed
Last Updated

May 27, 2016

Status Verified

April 1, 2016

Enrollment Period

11 months

First QC Date

April 11, 2012

Results QC Date

January 4, 2016

Last Update Submit

April 28, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Length of Stay

    The subjects will be evaluated preoperatively and followed post-operatively until discharge from the hospital. Length of stay

    From date of admission until date of discharge, assessed up to 1 month

Study Arms (2)

CHF peptide

ACTIVE COMPARATOR

Diuresis based on CHF-P

Drug: Furosemide

Non CHF peptide

ACTIVE COMPARATOR

Diuresis based on clinical judgement without data for CHF-P

Drug: Furosemide

Interventions

Based on clinical standard per clinician

Also known as: Brand name: Lasix
CHF peptideNon CHF peptide

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • General Surgery patients with history of coronary artery disease, congestive heart failure, pulmonary hypertension
  • Cardiac surgery patients undergoing CABG (coronary artery bypass grafting) and valve replacements

You may not qualify if:

  • Recent myocardial infarction (within 3 months).
  • ASA class 4 and more.
  • Emergency surgeries.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Creighton University Medical Center

Omaha, Nebraska, 68131, United States

Location

MeSH Terms

Interventions

Furosemide

Intervention Hierarchy (Ancestors)

SulfanilamidesSulfonamidesAmidesOrganic ChemicalsAniline CompoundsAminesSulfonesSulfur Compounds

Results Point of Contact

Title
Dr Anjan Talukdar
Organization
Creighton University

Study Officials

  • Anjan J Talukdar, MD

    Creighton University Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2012

First Posted

April 25, 2012

Study Start

July 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

May 27, 2016

Results First Posted

March 28, 2016

Record last verified: 2016-04

Locations